A key element in the benefit-risk assessment of medicines used for prophylaxis of venous thromboembolism (VTE) is balancing their antithrombotic effect with the risk of bleeding. Since the publication of the Committee for Medicinal Products for Human Use (CHMP) guidance on clinical investigation of medicinal products for the prophylaxis of VTE disease, a number of new European Medicines Agency (EMA) guidelines related to clinical investigation with antithrombotics have been released or are being revised. An update of the guideline on non-surgical patients, particularly related to the assessment of safety and bleeding events, is considered necessary to adapt its content to current scientific knowledge and to harmonise it with the content of the new or revised EMA guidelines related to clinical investigation with antithrombotics.

 

Posted on the EMA website on 16 July 2014